Boehringer Ingelheim strikes $7B backloaded ADC, TCE cancer deal with China's Sino

Germany's Boehringer Ingelheim is further planting its stake in China, teaming up with Sino Biopharmaceutical in a cancer drug development deal that could balloon past $7 billion. Boehringer is delivering $358 million ...